- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00390052
3-AP in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I and Pharmacokinetic Study of Oral 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone(3-AP,Triapine) in the Treatment of Advanced Solid Tumors
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES:
I. Determine the safety, tolerability, and toxicity of oral 3-AP in patients with advanced solid tumors.
II. Determine the maximum tolerated dose and recommended phase II dose of this drug in these patients.
III. Determine the oral bioavailability and pharmacokinetics of this drug. IV. Assess tumoral expression of genes involved in response and resistance to 3-AP.
V. Observe and record any tumor response in these patients.
OUTLINE: This is a multicenter, dose-escalation study.
Patients receive a one time dose of 3-AP IV over 2 hours on day -7. Patients then receive oral 3-AP twice daily on days 1-3, 8-10, and 15-17. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of oral 3-AP until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Blood samples for pharmacokinetic analysis are collected periodically over 8 hours after the IV dose of 3-AP and after the first oral dose of 3-AP during course 1.
After completion of study treatment, patients are followed periodically.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Criteria:
- Must be able to swallow
- Histologically confirmed solid tumor
- Advanced or metastatic disease
- Measurable or evaluable disease
- No known active CNS metastases
- ECOG performance status 0-1
- Life expectancy > 3 months
- Progressive disease during >= 1 prior standard therapy OR disease unlikely to respond to any currently available therapies
- Patients with previously treated CNS metastases who have no evidence of new CNS metastases AND are stable for >= 2 months are eligible
- Platelet count >= 100,000/mm^3
- Hemoglobin >= 10 g/dL (transfusions allowed)
- Absolute neutrophil count >= 1,500/mm^3
- ALT and AST =< 2.5 times upper limit of normal (ULN)
- Alkaline phosphatase =< 2.5 times ULN
- Creatinine =< 1.5 mg/dL OR creatinine clearance >= 50 mL/min
- Bilirubin normal
- PT/PTT =< 1.5 times ULN
- FEV1 >= 1.2 L
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception 2 weeks prior to and during study treatment
- No mental deficits and/or psychiatric history that may preclude study treatment
- No active heart disease, including any of the following: myocardial infarction within the past 3 months, symptomatic coronary artery disease or heart block, uncontrolled congestive heart failure
- No moderate to severe compromise of pulmonary function
- No active infection
- No other life-threatening illness
- No active coagulation disorder other than occult blood
- No known positivity for glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Recovered from prior treatment
- Prior gemcitabine allowed
- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- More than 3 weeks since prior radiotherapy or any other treatment for this cancer
- No prior 3-AP
- No concurrent radiotherapy
- No other concurrent investigational agent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
Patients will receive a 2-hour infusion of 3-AP once in week 1.
Beginning in week 2, they will receive 3-AP by mouth twice a day 3 days a week for 3 weeks.
Treatment with 3-AP by mouth may repeat every 4 weeks for as long as benefit is shown.
|
Given IV and orally
Other Names:
correlative study
Other Names:
Correlative study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose of oral 3-AP determined by dose-limiting toxicities graded according to the NCI CTCAE version 3.0
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum pharmacokinetics of oral triapine
Time Frame: Baseline, day 4, and day 8
|
Summary statistics of the pharmacokinetic parameters will be tabulated using the logarithmic scale where appropriate.
The relationship of the AUC to the dose will be assessed by least-square regression analysis.
|
Baseline, day 4, and day 8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yun Yen, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2009-00139 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U01CA062505 (U.S. NIH Grant/Contract)
- PHI-52 (Other Identifier: City of Hope)
- CDR0000507731
- 7225 (Other Identifier: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Adult Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingUnspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on triapine
-
Vion PharmaceuticalsCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
NCIC Clinical Trials GroupNational Cancer Institute (NCI)Completed
-
Vion PharmaceuticalsCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vion PharmaceuticalsCompleted
-
National Cancer Institute (NCI)CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic CancerUnited States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal CancerUnited States
-
Vion PharmaceuticalsCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7United States
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial CancerUnited States
-
Perry RenshawCompletedMajor Depressive DisorderUnited States